Publisher: Bentham Science Publishers
E-ISSN: 2212-3873|13|4|289-294
ISSN: 1871-5303
Source: Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol.13, Iss.4, 2013-12, pp. : 289-294
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Incretin-Based Therapies, Glucometabolic Health and Endovascular Inflammation
Current Pharmaceutical Design, Vol. 20, Iss. 31, 2014-09 ,pp. :
By Roges Octaviano A Baron Marilyn Philis-Tsimikas Athena
Expert Opinion on Investigational Drugs, Vol. 14, Iss. 6, 2005-06 ,pp. :
Benefits with incretin-targeted therapies in T2DM
Inpharma, Vol. 1, Iss. 1596, 2007-01 ,pp. :